| Today’s Big NewsApr 1, 2024 |
| By Fraiser Kansteiner Like clockwork, AstraZeneca CEO Pascal Soriot’s pay is under fire again. The two most influential proxy advisory firms are rallying investors to vote against the 2024 pay proposal for Soriot at the company’s annual general meeting this month. |
|
|
|
By Gabrielle Masson The biotech industry has been holding its breath, hoping that 2024 would bring some reprieve from 2023’s brutal bear market. But market recovery is a slow process, and the number of layoffs reported this quarter reflect that sentiment, with 57 layoff rounds reported for the first three months—the exact number reported during the same period last year. |
By Conor Hale You won’t see Abbott’s i-STAT Alinity test on the sidelines of sporting events just yet—but the FDA’s green light is a step in that direction, allowing the use of whole blood samples. |
By Zoey Becker The European Public Prosecutor’s Office (EPPO) took over the investigation into COVID vaccine negotiations between the European Commission's president and Pfizer's CEO Albert Bourla, Politico reports. |
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now! 
|
|
By Gabrielle Masson Carisma Therapeutics plans to let go of 37% of staffers and drop one of two clinical assets in an effort to fuel the immunotherapy-focused biotech into the third quarter of 2025. |
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
By Conor Hale First announced last December, the $375 million deal will see the launch of an independent, Colorado-based maker of screw and plate implants, fixation systems and bone healing technologies, among other spine products, under the new banner Highridge Medical. |
By Angus Liu What analysts viewed as a potential “inflection point” for Eisai and Biogen’s slow-footed Leqembi is facing a delay with the FDA. |
By Max Bayer Equillium’s add-on lupus treatment improved a biomarker of kidney function in an unblinded phase 1 study, setting the ball rolling toward Ono Pharmaceuticals’ court for future development work. |
By Kevin Dunleavy With AstraZeneca’s dominance in the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) threatened by the recent approval of the first pill on the market for the condition, Novartis’ Fabhalta, AstraZeneca has answered in the United States for its add-on oral treatment in the indication. |
By Helen Floersh Researchers for the first time have identified dysfunctional immune cells in the healthy breast tissue of women with mutations in the genes BRCA1 and BRCA2, a finding that opens up the possibility of using existing immunotherapy drugs to prevent cancer before it forms. |
By Andrea Park The fake product's packaging describes it as a pork-free semaglutide injection and “100% halal food”—complete with real Ozempic maker Novo Nordisk’s branding. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore our annual special report on the top money raisers in the biotech industry. Which company raised the most funding in 2023? What does the biotech financing landscape look like for this year? Fierce Biotech's Annalee Armstrong and Max Bayer answer those questions and many more in today's episode. |
|
|---|
|
|
|
Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this discussion on-demand to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now. 
|
|
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
